Meta Platforms Inc. (META)vsPfizer Inc (PFE)
META
Meta Platforms Inc.
$594.89
+0.33%
COMMUNICATION SERVICES · Cap: $1.50T
PFE
Pfizer Inc
$27.28
+1.19%
HEALTHCARE · Cap: $153.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Meta Platforms Inc. generates 221% more annual revenue ($200.97B vs $62.58B). META leads profitability with a 30.1% profit margin vs 12.4%. META appears more attractively valued with a PEG of 0.97. META earns a higher WallStSmart Score of 77/100 (B+).
META
Strong Buy77
out of 100
Grade: B+
PFE
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-5.4%
Fair Value
$562.36
Current Price
$594.89
$32.53 premium
Margin of Safety
-194.9%
Fair Value
$9.25
Current Price
$27.28
$18.03 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 30 in profit
Keeps 30 of every $100 in revenue as profit
Strong operational efficiency at 41.3%
Generating 14.8B in free cash flow
Growing faster than its price suggests
Large-cap with strong market position
Reasonable price relative to book value
Strong operational efficiency at 23.9%
Generating 4.5B in free cash flow
Areas to Watch
Moderate valuation
Weak financial health signals
Weak financial health signals
Expensive relative to growth rate
Revenue declined 1.2%
Earnings declined 21.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : META
The strongest argument for META centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 30.1% and operating margin at 41.3%. Revenue growth of 23.8% demonstrates continued momentum.
Bull Case : PFE
The strongest argument for PFE centers on Market Cap, Price/Book, Operating Margin.
Bear Case : META
The primary concerns for META are P/E Ratio, Piotroski F-Score.
Bear Case : PFE
The primary concerns for PFE are Piotroski F-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
META profiles as a growth stock while PFE is a declining play — different risk/reward profiles.
META carries more volatility with a beta of 1.28 — expect wider price swings.
META is growing revenue faster at 23.8% — sustainability is the question.
META generates stronger free cash flow (14.8B), providing more financial flexibility.
Bottom Line
META scores higher overall (77/100 vs 49/100), backed by strong 30.1% margins and 23.8% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Meta Platforms Inc.
COMMUNICATION SERVICES · INTERNET CONTENT & INFORMATION · USA
Meta Platforms, Inc. develops products that enable people to connect and share with friends and family through mobile devices, PCs, virtual reality headsets, wearables and home devices around the world. The company is headquartered in Menlo Park, California.
Visit Website →Pfizer Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.
Visit Website →Compare with Other INTERNET CONTENT & INFORMATION Stocks
Want to dig deeper into these stocks?